Skip to main content
Journal ArticleOPEN ACCESS

Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome

  • Macia M
  • de Alvaro Moreno F
  • Dutt T
  • et al.
Clinical Kidney Journal (2017) sfw115
DOI: 10.1093/ckj/sfw115
N/ACitations
Citations of this article
71Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disorder for which eculizumab is the only approved treatment. Life-long treatment is indicated; however, eculizumab discontinuation has been reported.

Cite

CITATION STYLE

APA

Macia, M., de Alvaro Moreno, F., Dutt, T., Fehrman, I., Hadaya, K., Gasteyger, C., & Heyne, N. (2017). Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clinical Kidney Journal, sfw115. https://doi.org/10.1093/ckj/sfw115

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free